Published on 29 de June de 2018 | http://doi.org/10.5867/medwave.2018.03.7220
Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile
Components of BSC used in the model.
